IP Library Granted Patent US 10,638,735
Granted Patent B2
US 10,638,735 · App. 14/962,335 · Granted May 5, 2020

Generation of heavy-chain only antibodies in transgenic animals

Inventors: Franklin Gerardus Grosveld (Rotterdam, NL); Richard Wilhelm Janssens (Rotterdam, NL); Roger Kingdon Craig (Sandbach, GB)
Assignee: Erasmus University Medical Center
A01K67/0278C07K16/00C07K16/1009C07K16/1232C07K16/1282C07K16/1285C07K16/241C12N15/8509A01K2207/15A01K2217/00A01K2217/05A01K2217/072A01K2217/075A01K2227/105A01K2267/01C07K2317/24C07K2317/569C12N2015/8518
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,638,735
App. No.
14/962,335
Granted
May 5, 2020
Kind
B2
Abstract

The present invention relates to a method for the generation of V H heavy chain-only antibodies in a transgenic non-human mammal. In particular, the present invention relates to a method for the production of a V H heavy chain-only antibody in a transgenic non-human mammal comprising the step of expressing more than one heterologous V H heavy chain locus in that mammal.

Claims (26)

1. A method for increasing the diversity of V H heavy chain-only antibodies in a transgenic non-human mammal comprising the steps of

a) providing a transgenic non-human mammal whose genome comprises more than one heterologous V H heavy chain locus, wherein each V H heavy chain locus comprises naturally occurring V H gene segments of human origin, D gene segments, and J gene segments, and a gene segment encoding a heavy chain constant region which, when expressed, does not include a functional C H 1 domain and

b) expressing a V H heavy chain-only antibody from at least one of said loci in B-cells,

wherein said heterologous V H heavy chain loci are present on the same or different chromosomes, and the expression of a heterologous V H locus is determined by allelic exclusion.

2. The method of claim 1 , wherein each locus comprises only one V gene segment.

3. The method of claim 1 , wherein each V gene segment is different from all other V gene segments.

4. The method of claim 1 , wherein the multiple V H heavy chain loci comprise any number or combination of the 39 functional human V gene segments.

5. The method of claim 4 , wherein each different V H heavy chain locus is present as a single copy in the genome of the transgenic non-human mammal.

6. The method of claim 1 , wherein each V H heavy chain locus comprises from one to forty D gene segments.

7. The method of claim 1 , wherein the D gene Segments are human D gene segments.

8. The method of claim 1 , wherein each V H heavy chain locus comprises from one to twenty J gene segments.

9. The method of claim 1 , wherein the J gene segments are human J gene segments.

10. The method of claim 1 , wherein each V H heavy chain locus comprises one or more V gene segments, twenty-five functional human D gene segments and 6 human J gene segments.

11. The method of claim 1 , wherein each gene segment encoding a heavy chain constant region comprises one or more heavy chain constant region exons of the Cδ, Cγ 1-4 , Cμ, Cε or Cα 1-2 classes, with the proviso that the heavy chain constant region gene segments do not express a C H 1 domain.

12. The method of claim 1 , wherein the heavy chain constant region is of human origin.

13. The method of claim 1 , wherein the transgenic non-human mammal is a rodent.

14. The method of claim 13 , wherein the rodent is a mouse.

15. A transgenic non-human mammal comprising more than one heterologous V H heavy chain locus as defined in claim 1 .

16. A method for the production of heavy chain-only antibodies comprising:

a) immunising a transgenic non-human mammal of claim 15 with an antigen; and

b) isolating antigen-specific heavy chain-only antibodies.

17. A method of producing high affinity, antigen-specific V H heavy chain-only antibodies comprising:

a) immunising a transgenic non-human mammal according to claim 15 with an antigen;

b) generating B-cell hybridomas;

c) selecting cells expressing antigen-specific heavy chain-only antibody; and

d) isolating antigen-specific heavy chain-only antibody.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 9, 2023
From: ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
To: HARBOUR ANTIBODIES B.V.
Reel/Frame 065157/0018 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 4, 2016
From: GROSVELD, FRANKLIN GERARDUS; JANSSENS, RICHARD WILHELM
To: ERASMUS UNIVERSITY MEDICAL CENTER
Reel/Frame 038184/0446 →
Priority Claims (2)
GB 0601511.9 · Jan 25, 2006 · national
GB 0618345.3 · Sep 18, 2006 · national
Continuity (2)
Continuation 12161981
Related Publication 20160295843A1 · Oct 13, 2016
Cited By (1)
US 12,588,664